We have examined by immunohistochemistry the ability of breast carcinomas to produce pepsinogen C, an aspartyl proteinase usually involved in the digestion of proteins in the stomach. A total of 113 out of 245 breast tumours (46%) were positive for pepsinogen C immunostaining. There was a significant association between pepsinogen C and oestrogen receptors with proteinase levels higher (HSCORE) in oestrogen receptor positive tumours than in oestrogen receptor negative. There was also a significant association between pepsinogen C and histological grade, pepsinogen C levels being higher in well and moderately differentiated breast carcinomas than in poorly differentiated tumours. On the basis of these results, we suggest that pepsinogen C may be useful as a marker of good prognosis in breast cancer.
Breast tumour cells are known to overproduce or to induce stromal cells to elaborate a variety of proteolytic enzymes including metalloproteinases like collagenases and stromelysins (Monteagudo et al., 1990; Basset et al., 1990) , aspartyl-proteinases such as cathepsin D (Rochefort et al., 1987; S'anchez et al., 1993) , serine-proteinases like plasminogen activators (Sappino et al., 1987) or cysteine proteinases such as cathepsins B and L (Sloane et al., 1981; Chauhan et al., 1991) . All of them are secreted as precursors of higher molecular weight that, after activation, may contribute to degrade the extracellular matrix, thereby facilitating tumour growth, invasion and metastasis (Liotta, 1988) . A series of clinical studies has provided additional support to this proposed role for proteinases in breast cancer. Thus, and although data are not univocal (Duffy et al., 1988; Henry et al., 1990) , the increased expression of proteolytic enzymes in breast carcinomas has been usually correlated with a poor clinical outcome of the disease (Spyratos et al., 1989; Tandon et al., 1990; Duffy et al., 1990) .
As part of our studies directed to investigate the involvement of proteolytic enzymes in breast cancer, we have recently described that some breast carcinomas and mammary epithelium surrounding breast cysts produce an aspartyl-proteinase closely related to gastric pepsinogen C (Sa'nchez et al., 1992a) . The finding of this new proteinase produced by pathological breast tissue prompted us to evaluate its potential interest as a tumour marker. In this work, we have studied its expression in a series of 245 breast tumours by using immunohistochemical staining. In addition, we have examined the possible correlation of these results on pepsinogen C expression with the most common prognostic parameters in breast cancer.
Antiserum against the purified protein was raised in rabbits as described by Vaitukaitis (1981) , and its specificity confirmed by immunoblot analysis as previously described (Sanchez et al., 1992b) .
Immunohistochemical assays were performed on 6 gAm formalin-fixed paraffin-embedded tissue sections using the avidin-biotin method (Hsu et al., 1981) . Slides were scored according to the procedure described by McCarty et al. (1986) , which incorporates both the intensity (I) and the percentage of cells staining at each intensity (PC). Intensities were classified from 0 (no staining) to 3 (very strong staining). For each tissue section, a value designated HSCORE (McCarty et al., 1986) was obtained by applying the following algorithm: HSCORE = E((I + 1) x PC). Statistical analysis of data was performed using Student's t-test or ANOVA-test followed by the post-ANOVA Newman-Keuls test. Table I shows the clinical characteristics of the 245 patients included in this study. Pepsinogen C expression in the corres- Table  I . Tumours were graded histologically according to the criteria of Bloom and Richardson (1957) . Nodal status was assessed histopathologically.
Results
Pepsinogen C was purified from human stomach as previously described (Foltmann & Jensen 1982) Figure 2 .
To determine the possible relationship between pepsinogen C expression and disease status, women included in the study .EI d Figure 2 Immunohistochemical staining of pepsinogen C in human breast cancer. Positive tumours a,b, negative tumour c and gastric mucosa d. Tissues sections were immunostained with anti-gastric pepsinogen C (1:600 dilution). Sections were counterstained with formaldehyde-thionine (Tolivia & Tolivia, 1985) . Original magnification a,c,d 160 X; (b) 250 x.
were classified into different groups according to several clinopathological parameters and the presence of the proteinase was evaluated in each group. To investigate the possible relationship between pepsinogen C expression and oestrogen receptor status in breast tumours, we compared the HSCORE pepsinogen C values with the tumour cytosolic concentration of this biochemical parameter measured by enzyme immunoassay. As shown in Table II , the average concentration of the proteinase was higher in ER+ tumours (>10 fmol mg-1) than in those ER-(90.5 vs 47.3). Statistical analysis revealed that these differences were significant (P<0.05).
Discussion
Our preliminary finding indicating that some breast tumours produce pepsinogen C (Sa'nchez et al., 1992a), a gastric proteinase mainly involved in the digestion of proteins in the stomach (Samloff, 1989) , prompted us to study the expression of this enzyme in a large series of breast carcinomas. The results obtained have provided evidence that more than 40% of these tumours present immunohistochemically detectable pepsinogen C. In addition, a considerable variation in both the proportion of tumour cells expressing the proteinase and the intensity of staining was observed. This wide variability may reflect the existence of breast tumours differing in clinical behaviour, which could be of importance in relation to the possible value of pepsinogen C as a new prognostic marker in breast cancer.
As a first step to examine this question, and considering the short follow-up of patients whose tumour pepsinogen C values have been determined in the present work, we tried to find correlations of this zymogen with common prognostic factors in breast carcinoma. These analyses revealed the absence of a significant relationship between pepsinogen C expression and several patient and tumour characteristics such as axillary node status, menopausal status and tumour size. By contrast, expression levels of the proteinase were significantly associated with the histological grade of tumours and oestrogen receptor status. Thus, higher levels of pepsinogen C were found in well and moderately differentiated tumours than in those poorly differentiated. Similarly, pepsinogen C values were higher in oestrogen receptor positive tumours. Considering that both conditions confer a prognostic advantage to breast cancer patients, it is tempting to speculate that pepsinogen C expression may be a marker of good prognosis in breast cancer.
The finding of proteolytic enzymes indicative of lesions with favorable evolution is not unprecedented. Thus, tissuetype plasminogen activator (t-PA) is associated to breast tumours that present a favourable prognosis (Duffy et al., 1988) . In addition, and although most authors have proposed that cathepsin D is a marker of poor clinical outcome of the disease, Henry et al. (1990) have suggested that this oestrogen-induced proteinase is a marker of good prognosis in breast cancer. Since cathepsin D is a widely distributed enzyme, these discrepancies have been attributed to the low specificity of biochemical assays based on tumour extracts containing a variable number of non-tumour cathepsin D producing cells, although other explanations like different properties of antibodies used or variations in the follow-up period cannot be ruled out (Isola et al., 1993; Winstanley et al., 1993) . In this regard, the finding that pepsinogen C is not produced by normal resting mammary gland together with its highly restricted expression in human tissues (Samloff, 1989) , may be of importance in relation to its value as a tumour marker in breast cancer since it could offer advantages over those widely expressed biochemical markers. The long-term clinical follow-up of women whose tumours have been analysed in this work, will be useful to define the biological significance of the expression of this gastric zymogen by breast tumour cells and its prognostic significance in breast cancer.
